{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.2","upperLimit":"18.4","value":"11.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"PFS is defined as the number of days from the date of the first dose of study treatment to the date of first documented disease progression or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG000","title":"Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"MEDIAN","populationDescription":"All enrolled Phase 2 participants who received venetoclax and had active disease at baseline; this endpoint was pre-specified for Phase 2 only, data are reported for all participants with available data","reportingStatus":"POSTED","timeFrame":"Estimated median duration of follow-up was 31.7 months","title":"Phase 2: Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}